Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Gene | CHEK1 |
Variant | positive |
Impact List | unknown |
Protein Effect | unknown |
Gene Variant Descriptions | CHEK1 positive indicates the presence of the CHEK1 gene, mRNA, and/or protein. |
Associated Drug Resistance | |
Category Variants Paths |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
CHEK1 positive | lung non-small cell carcinoma | predicted - sensitive | Prexasertib | Preclinical - Cell line xenograft | Actionable | In a preclinical study, Prexasertib (LY2606368) increased apoptosis of non-small cell lung cancer (NSCLC) cells in culture, and inhibited Chek1 phosphorylation, induced DNA damage, and reduced tumor growth in a NSCLC cell line xenograft model (PMID: 26141948). | 26141948 |
CHEK1 positive | head and neck squamous cell carcinoma | sensitive | CCT244747 + Radiotherapy | Preclinical - Cell culture | Actionable | In a preclinical study, CCT244747 inhibited Chek1 activation, resulted in sensitizing head and neck squamous cell carcinoma cell lines to radiation treatment in culture (PMID: 27422809). | 27422809 |
CHEK1 positive | head and neck squamous cell carcinoma | sensitive | CCT244747 + Paclitaxel + Radiotherapy | Preclinical - Cell line xenograft | Actionable | In a preclinical study, CCT244747, Taxol (paclitaxel), and radiation triple therapy synergistically inhibited Chek1 activation, and resulted in growth inhibition of head and neck squamous cell carcinoma cell lines in culture and in cell line xenograft models (PMID: 27422809). | 27422809 |
CHEK1 positive | colon cancer | predicted - sensitive | CCT244747 + Gemcitabine | Preclinical - Cell line xenograft | Actionable | In a preclinical study, the combination of CCT244747 and Gemzar (gemcitabine) slowed tumor growth to a greater degree than treatment with either agent alone and decreased Chek1 phosphorylation in colon cancer cell line xenograft models (PMID: 22929806). | 22929806 |